September 8, 2020
A key health ministry advisory committee on September 4 gave its thumbs up to Rakuten Medical’s sakigake -designated antibody drug conjugate (ADC) (cetuximab sarotalocan sodium), based on its photoimmunotherapy technology platform, placing the drug in line for approval in September,...read more